Latest:
Dr Tao on the Efficacy of Avelumab/Cetuximab/Radiotherapy in Cisplain-Eligibile vs Ineligible HNSCC
Yungan Tao, MD, discusses the efficacy of avelumab plus cetuximab and radiotherapy in patients with head and neck squamous cell carcinoma.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Vanda Salutari, MD
Vanda Salutari, MD, is an oncologist in the Department of Health of Woman and Child at the Catholic University of Sacred Heart, in Rome, Italy.
Latest:
Dr Salutari on the Rationale for Evaluating Relacorilant Plus Nab-Paclitaxel in PARP Inhibitor–Treated PROC
Vanda Salutari, MD, discusses the rationale for examining relacorilant plus nab-paclitaxel in PARP inhibitor–treated platinum-resistant ovarian cancer.
Jason Ye, MD
Jason Ye, MD, is the director of Clinical Operations of Radiation Oncology at University of Southern California (USC) Norris Comprehensive Cancer Hospital and associate professor of Clinical Radiation at Keck School of Medicine of USC.
Latest:
Coordinated Care in Breast Oncology: Encouraging Participation in Clinical Trials
Experts reflect on the power of clinical trial participation, multidisciplinary collaboration, and innovation to personalize care.
Mark Faries, MD
Mark Faries, MD, is a surgical oncologist at Cedars‑Sinai and The Angeles Clinic and Research Institute. He also serves as associate director of Surgical Oncology Experimental Therapeutics in the Cedars Sinai Department of Surgery, and is head of surgical oncology at Cedars-Sinai Medical Center.
Latest:
Dr Faries on Emerging CAR T-Cell and TCR Cell Therapies in Melanoma
Mark Faries, MD, discusses how CAR T-cell and TCR cell therapies compare with TIL approaches in melanoma.
Monica Janke, MD
Latest:
Virtual Surveillance Visits with Symptom, Serum CA-125 Review May Offer Alternative for Ovarian Cancer Recurrence Detection.
In patients with ovarian cancer and pretreatment elevated CA-125 who achieved remission after frontline therapy, most recurrences are detected by rising CA-125 levels or symptoms.
Qi Cheng, MD
Qi Cheng, MD is a medical doctor at Huazhong University of Science and Technology.
Latest:
Dr Cheng on the Safety and Efficacy of Irpagratinib Plus Atezolizumab in Advanced HCC
Qi Cheng, MD, discusses the safety and efficacy of irpagratinib plus atezolizumab in advanced hepatocellular carcinoma.
Antoinette R. Tan, MD, MHSc
Latest:
Dr. Tan on the Potential of Elacestrant in the EMERALD Trial in ER+ Breast Cancer
Antoinette R. Tan, MD, MHSc, discusses the potential of the oral selective estrogen receptor degrader elacestrant being investigated in the phase 3 EMERALD trial in estrogen receptor–positive breast cancer.